Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » Bayern Nordic wins additional contract for MPOX vaccine in the US
Vaccines

Bayern Nordic wins additional contract for MPOX vaccine in the US

Paul E.By Paul E.September 25, 2024No Comments3 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Bayern Nordic has been awarded a $63 million contract by the U.S. government to produce additional bulk product and finished lyophilized doses of the JYNNEOS smallpox/mpox vaccine.

The order, received from the U.S. Biomedical Advanced Research and Development Authority, is intended to replenish bulk product inventories and support the production of one million doses of the vaccine.

Bulk products, which account for the majority of the contract value, are essential to replenish depleted stocks during the 2022 MPOX outbreak response.

The replenishment is essential to meet the terms of Bayern Nordic’s existing contracts, including the supply of freeze-dried vaccine for the US smallpox program.

The contract will allow the production of 1 million doses of freeze-dried vaccine using part of the company’s large inventory.

The bulk of the vaccine is expected to be manufactured in 2025, but deliveries of the freeze-dried vaccine are scheduled for 2026, keeping in mind international orders to combat the ongoing MPOX epidemic.

Paul Chaplin, President and CEO of Bayern Nordic, said: “This award further strengthens our public protection business portfolio beyond 2025 and once again represents strong endorsement of MVA-BN as a leader in smallpox and multiple sclerosis vaccines.”

“The current smallpox outbreak is a reminder of how vulnerable the global community is to infectious diseases, but we remain committed to supporting all governments and organizations to ensure equitable access to variola/smallpox vaccines during the current public health emergency and beyond.”

The modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) nonreplicating mpox vaccine, marketed as JYNNEO, has been approved in Canada, the European Union, Mexico, Singapore, Switzerland, the United Kingdom, and the United States.

MVA-BN was originally developed as a smallpox vaccine in partnership with the U.S. government and was designed to ensure adequate vaccine supply for the entire population, including those who are immunocompromised and not recommended to receive the traditional replicating smallpox vaccine.

This latest development comes after the European Medicines Agency (EMA) approved Bayer Nordic’s mpox vaccine for use in adolescents, raising the possibility of its use in this age group in Africa.

The Global Alliance for Vaccines and Immunisation recently signed an advance purchase agreement with Bayer Nordic AG to secure 500,000 doses of the mpox vaccine.

“Bavarian Nordic Wins Additional MPOX Vaccine Contract in US” was originally produced and published by Pharmaceutical Technology, a brand owned by GlobalData.

The story continues

The information on this site is published in good faith for general information purposes only. It is not intended to amount to advice on which you should rely and we make no representations, warranties or guarantees, express or implied, as to its accuracy or completeness. You should always obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on this site.



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleWest Virginia must innovate in health care to become economically competitive • West Virginia Watch
Next Article Clear the Crib Challenge encourages high school sports teams and mascots to spread message
Paul E.
  • Website

Related Posts

Kentucky leaders emphasize whooping cough vaccination

October 31, 2024

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

October 31, 2024

Trust is important, but increasing vaccination rates also requires three things

October 31, 2024
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.